BR112022008516A2 - Métodos de tratamento com anticorpos contra bcma e cd3 - Google Patents

Métodos de tratamento com anticorpos contra bcma e cd3

Info

Publication number
BR112022008516A2
BR112022008516A2 BR112022008516A BR112022008516A BR112022008516A2 BR 112022008516 A2 BR112022008516 A2 BR 112022008516A2 BR 112022008516 A BR112022008516 A BR 112022008516A BR 112022008516 A BR112022008516 A BR 112022008516A BR 112022008516 A2 BR112022008516 A2 BR 112022008516A2
Authority
BR
Brazil
Prior art keywords
methods
bcma
treatment
antibodies against
against bcma
Prior art date
Application number
BR112022008516A
Other languages
English (en)
Inventor
Burgess Michael
Hege Kristen
Datta Kaushik
BOSS Isaac
Diem VU Minh
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BR112022008516A2 publication Critical patent/BR112022008516A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

MÉTODOS DE TRATAMENTO COM ANTICORPOS CONTRA BCMA E CD3. A presente invenção refere-se a métodos de tratar um paciente com um distúrbio associado com expressão de BCMA (por exemplo, cânceres de célula B que expressam BCMA, tal como, mieloma múltiplo) usando regimes de dosagem de escanolamento de dose com anticorpos multiespecíficos (por exemplo, biespecíficos) que se ligam a CD3 e BCMA.
BR112022008516A 2019-11-05 2020-11-04 Métodos de tratamento com anticorpos contra bcma e cd3 BR112022008516A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19207293 2019-11-05
EP20179573 2020-06-11
PCT/US2020/058939 WO2021092056A1 (en) 2019-11-05 2020-11-04 Methods of treatment with antibodies against bcma and cd3

Publications (1)

Publication Number Publication Date
BR112022008516A2 true BR112022008516A2 (pt) 2022-08-30

Family

ID=75849140

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008516A BR112022008516A2 (pt) 2019-11-05 2020-11-04 Métodos de tratamento com anticorpos contra bcma e cd3

Country Status (11)

Country Link
US (1) US20230057602A1 (pt)
EP (1) EP4054725A4 (pt)
JP (1) JP2022553822A (pt)
KR (1) KR20220093141A (pt)
CN (1) CN115279459A (pt)
AU (1) AU2020379757A1 (pt)
BR (1) BR112022008516A2 (pt)
CA (1) CA3160137A1 (pt)
IL (1) IL292704A (pt)
MX (1) MX2022005292A (pt)
WO (1) WO2021092056A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2352765B1 (en) * 2008-10-01 2018-01-03 Amgen Research (Munich) GmbH Cross-species-specific single domain bispecific single chain antibody
PT3331910T (pt) * 2015-08-03 2020-03-24 Engmab Sarl Anticorpos monoclonais contra o antigénio de maturação de células b (bcma) humano
CN110167964B (zh) * 2016-11-02 2023-12-01 百时美施贵宝公司 组合用于治疗多发性骨髓瘤的针对bcma和cd3的双特异性抗体和免疫药物

Also Published As

Publication number Publication date
KR20220093141A (ko) 2022-07-05
IL292704A (en) 2022-07-01
CA3160137A1 (en) 2021-05-14
EP4054725A4 (en) 2024-01-10
US20230057602A1 (en) 2023-02-23
AU2020379757A1 (en) 2022-05-26
MX2022005292A (es) 2022-08-10
WO2021092056A1 (en) 2021-05-14
CN115279459A (zh) 2022-11-01
JP2022553822A (ja) 2022-12-26
EP4054725A1 (en) 2022-09-14

Similar Documents

Publication Publication Date Title
PE20190392A1 (es) Antianticuerpos gprc5d, moleculas de union al antigeno biespecificas que se unen a gprc5d y cd3, y usos de estas
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
PH12018500363A1 (en) Bispecific monovalent diabodies that are capable of binding b7-h3 and cd3, and uses thereof
BR112018012801A2 (pt) combinação de anticorpos anti-pd-1 e anticorpos biespecíficos anti-cd20/anti-cd3 para tratar o câncer
PE20180795A1 (es) Anticuerpos anti-bcma, moleculas de union a antigenos biespecificas que se unen a bcma y cd3, y uso de estos
MX2018010733A (es) Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
MX2020004948A (es) Receptor de antígeno quimérico que selecciona como diana bcma, receptor de antígeno quimérico que selecciona como diana cd19 y terapias de combinación.
EA201791171A1 (ru) Антитела к tigit
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
MX2017015811A (es) Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
MX2017017049A (es) Anticuerpos anti antigeno de celulas nk y linfocitos t y b (ntb-a) y composiciones y metodos relacionados.
CL2015002223A1 (es) Objetivo terapéutico y diagnostico.
JOP20200309A1 (ar) أجسام مضادة لـ il-11
MX2018008934A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso.
BR112021023026A2 (pt) Moléculas de ligação biespecíficas anti-ror1/anti-cd3
BR112021020409A2 (pt) Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase
NZ631082A (en) Methods for treating cancer using tor kinase inhibitor combination therapy
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
BR112019023909A2 (pt) método para tratamento de um paciente com câncer de ovário, câncer peritoneal ou câncer de trompa de falópio.
MX2018013525A (es) Construcciones de anticuerpo de adn para uso contra pseudomonas aeruginosa.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
PH12020552059A1 (en) Dosing regimen for the treatment of pi3k related disorders
MX2021010116A (es) Anticuerpo anti-pd-l1 y uso de este.